JP2019516693A - 小細胞肺がんの治療に使用するためのナノリポソームイリノテカン - Google Patents

小細胞肺がんの治療に使用するためのナノリポソームイリノテカン Download PDF

Info

Publication number
JP2019516693A
JP2019516693A JP2018559186A JP2018559186A JP2019516693A JP 2019516693 A JP2019516693 A JP 2019516693A JP 2018559186 A JP2018559186 A JP 2018559186A JP 2018559186 A JP2018559186 A JP 2018559186A JP 2019516693 A JP2019516693 A JP 2019516693A
Authority
JP
Japan
Prior art keywords
irinotecan
sclc
administration
human patient
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018559186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516693A5 (enExample
Inventor
バンバン アディウィジャヤ，
バンバン アディウィジャヤ，
ジョナサン バジル フィッツジェラルド，
ジョナサン バジル フィッツジェラルド，
ヘレン リー，
ヘレン リー，
Original Assignee
イプセン バイオファーム リミティド
イプセン バイオファーム リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イプセン バイオファーム リミティド, イプセン バイオファーム リミティド filed Critical イプセン バイオファーム リミティド
Publication of JP2019516693A publication Critical patent/JP2019516693A/ja
Publication of JP2019516693A5 publication Critical patent/JP2019516693A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018559186A 2016-05-18 2017-05-17 小細胞肺がんの治療に使用するためのナノリポソームイリノテカン Withdrawn JP2019516693A (ja)

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
US201662337961P 2016-05-18 2016-05-18
US62/337,961 2016-05-18
US201662345178P 2016-06-03 2016-06-03
US62/345,178 2016-06-03
US201662362735P 2016-07-15 2016-07-15
US62/362,735 2016-07-15
US201662370449P 2016-08-03 2016-08-03
US62/370,449 2016-08-03
US201662394870P 2016-09-15 2016-09-15
US62/394,870 2016-09-15
US201662414050P 2016-10-28 2016-10-28
US62/414,050 2016-10-28
US201662415821P 2016-11-01 2016-11-01
US62/415,821 2016-11-01
US201662422807P 2016-11-16 2016-11-16
US62/422,807 2016-11-16
US201662433925P 2016-12-14 2016-12-14
US62/433,925 2016-12-14
US201762455823P 2017-02-07 2017-02-07
US62/455,823 2017-02-07
US201762474661P 2017-03-22 2017-03-22
US62/474,661 2017-03-22
PCT/IB2017/000681 WO2017199093A1 (en) 2016-05-18 2017-05-17 Nanoliposomal irinotecan for use in treating small cell lung cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020085131A Division JP2020117548A (ja) 2016-05-18 2020-05-14 小細胞肺がんの治療に使用するためのナノリポソームイリノテカン

Publications (2)

Publication Number Publication Date
JP2019516693A true JP2019516693A (ja) 2019-06-20
JP2019516693A5 JP2019516693A5 (enExample) 2020-06-25

Family

ID=59258274

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018559186A Withdrawn JP2019516693A (ja) 2016-05-18 2017-05-17 小細胞肺がんの治療に使用するためのナノリポソームイリノテカン
JP2020085131A Withdrawn JP2020117548A (ja) 2016-05-18 2020-05-14 小細胞肺がんの治療に使用するためのナノリポソームイリノテカン
JP2021185609A Pending JP2022010295A (ja) 2016-05-18 2021-11-15 小細胞肺がんの治療に使用するためのナノリポソームイリノテカン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020085131A Withdrawn JP2020117548A (ja) 2016-05-18 2020-05-14 小細胞肺がんの治療に使用するためのナノリポソームイリノテカン
JP2021185609A Pending JP2022010295A (ja) 2016-05-18 2021-11-15 小細胞肺がんの治療に使用するためのナノリポソームイリノテカン

Country Status (16)

Country Link
US (1) US20230000858A1 (enExample)
EP (1) EP3458059A1 (enExample)
JP (3) JP2019516693A (enExample)
KR (1) KR20190009319A (enExample)
CN (1) CN109640995A (enExample)
AU (1) AU2017267449A1 (enExample)
BR (1) BR112018072988A2 (enExample)
CA (1) CA3023743A1 (enExample)
IL (1) IL262656A (enExample)
MA (1) MA45046A (enExample)
MX (1) MX394766B (enExample)
PH (1) PH12018502422A1 (enExample)
SG (2) SG11201809788VA (enExample)
TW (1) TWI791437B (enExample)
UA (1) UA125646C2 (enExample)
WO (1) WO2017199093A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
HK1257216A1 (zh) 2015-08-20 2019-10-18 益普生生物制药有限公司 使用脂质体伊立替康和parp抑制剂用於癌症治疗的组合疗法
BR112018002941B1 (pt) 2015-08-21 2023-12-05 Ipsen Biopharm Ltd Uso de irinotecano lipossomal, oxaliplatina, leucovorina e 5- fluorouracil no tratamento de primeira linha de adenocarcinoma metastático do pâncreas
BR112018006922B1 (pt) 2015-10-16 2023-11-21 Ipsen Biopharm Ltd Composições de irinotecano lipossômico estabilizado para armazenamento
CN110402163A (zh) 2016-11-02 2019-11-01 易普森生物制药有限公司 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012092119A (ja) * 2004-05-03 2012-05-17 Hermes Biosciences Inc 薬物送達に有用なリポソーム
JP2015523355A (ja) * 2012-06-13 2015-08-13 メリマック ファーマシューティカルズ インコーポレーティッド リポソームイリノテカンを含む併用療法を用いた、膵臓癌を治療するための方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2550759T3 (es) * 2007-08-17 2015-11-12 Celator Pharmaceuticals, Inc. Formulaciones farmacológicas de platino mejoradas

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012092119A (ja) * 2004-05-03 2012-05-17 Hermes Biosciences Inc 薬物送達に有用なリポソーム
JP2015523355A (ja) * 2012-06-13 2015-08-13 メリマック ファーマシューティカルズ インコーポレーティッド リポソームイリノテカンを含む併用療法を用いた、膵臓癌を治療するための方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHAN DANIEL C: "EVALUATING THE PHARMACODYNAMICS AND PHARMACOKINETIC EFFECTS OF MM-398, A NANOLIPOSOMAL 以下備考", CANCER RESEARCH, JPN5019004722, October 2014 (2014-10-01), pages 1 - 4, ISSN: 0004476066 *
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, vol. 44(9), JPN6021011617, 2014, pages 846 - 851, ISSN: 0004476065 *

Also Published As

Publication number Publication date
CN109640995A (zh) 2019-04-16
IL262656A (en) 2018-12-31
SG11201809788VA (en) 2018-12-28
BR112018072988A2 (pt) 2019-04-09
UA125646C2 (uk) 2022-05-11
MX394766B (es) 2025-03-24
EP3458059A1 (en) 2019-03-27
JP2022010295A (ja) 2022-01-14
TW201740946A (zh) 2017-12-01
SG10201912407YA (en) 2020-02-27
JP2020117548A (ja) 2020-08-06
CA3023743A1 (en) 2017-11-23
TWI791437B (zh) 2023-02-11
MX2018013873A (es) 2019-02-14
US20230000858A1 (en) 2023-01-05
WO2017199093A1 (en) 2017-11-23
AU2017267449A1 (en) 2018-11-15
KR20190009319A (ko) 2019-01-28
MA45046A (fr) 2019-03-27
PH12018502422A1 (en) 2019-03-11

Similar Documents

Publication Publication Date Title
US20230000858A1 (en) Nanoliposomal Irinotecan for Use in Treating Small Cell Lung Cancer
JP6857210B2 (ja) リポソームイリノテカンを含む併用療法を用いた、膵臓癌を治療するための方法
US11318131B2 (en) Nanoliposomal irinotecan for use in treating small cell lung cancer
US11071726B2 (en) Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)
WO2016168451A1 (en) Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment
US20210205293A1 (en) Combination of topoisomerase-i inhibitors with immunotherapy in the treatment of cancer
TW202337469A (zh) 治療小細胞肺癌之方法
JP2004518717A (ja) 標的化された抗腫瘍剤送達系
KR20170002600A (ko) 항-ｅｇｆｒ 치료제의 투여량 및 투여
TW202425991A (zh) 阿森色替於治療癌症中之間歇性給藥方案
HK40005832A (en) Nanoliposomal irinotecan for use in treating small cell lung cancer
TW202504587A (zh) Ｓｔａｔ３降解劑及其用途
Srinivasan et al. Brain Metastases: Molecules to Medicine
RU2808427C2 (ru) Способы лечения рака поджелудочной железы с применением комбинированной терапии, включающей липосомальный иринотекан

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200514

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210330

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210524

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20210929